Washington, D.C. (April 7, 2022) – “Today, the Centers for Medicare and Medicaid Services (CMS) issued its final coverage ruling for an entire class of Alzheimer’s drugs. At its core, this National Coverage Decision (NCD) is not very different here from a flat-out denial of coverage.
CMS continues to treat all Alzheimer’s patients differently than any other class of patients. No coverage to label restricts the drugs to only a few patients and guts the Food and Drug Administration’s (FDA) accelerated approval program.
This decision will affect the future of Alzheimer’s treatments for at least the next 10 years, representing a crushing blow for the more than six million Americans with Alzheimer’s who were depending on CMS to approve these treatment options.
###
About the Global Alzheimer’s Platform Foundation® (GAP)
The Global Alzheimer’s Platform Foundation® (GAP) is a person-centric nonprofit dedicated to accelerating the delivery of innovative therapies for neurological disorders by reducing the duration and cost of clinical trials. Research centers across the US, Canada, and Europe are part of the growing GAP Network (GAP-Net). GAP supports GAP-Net research centers by assisting with study start up and recruitment activities, promoting diversity in research studies, and offering international clinical trial infrastructure, resources, and programs that champion brain health and the citizen scientists who make research possible.